Source document: acura-pharmaceuticals-inc_2019

Question: What are the primary factors that caused a negative balance in operating activities in 2019?
Facts: Net cash used in operating activities was $0.6 million for the year ended December 31, 2019 and consisted primarily of a net loss of $3.8 million, capitalized debt discount of $13 thousand and a loss on debt extinguishment of $2.6 million.
Answer: Net cash used in operating activities was $0.6 million for the year ended December 31, 2019 and consisted primarily of a net loss of $3.8 million, capitalized debt discount of $13 thousand and a loss on debt extinguishment of $2.6 million.

Question: How much cash was provided from financing activities in 2018?
Facts: $1.8 million
Answer: $1.8 million

Question: What are the investing activities in 2018 and 2019?
Facts: We had no investing activities for the years ended December 31, 2019 and 2018.
Answer: We had no investing activities for the years ended December 31, 2019 and 2018.

Question: What is the difference in cash used in operating activities during 2018 and 2019?
Facts: 3,908; 618
Derivation: 3,908 - 618 
Answer: 3290 thousand

Question: What is the percentage increase in cash provided from financing activities between 2018 and 2019?
Facts: 1,389; 1,779
Derivation: (1,389 - 1,779) / 1,779 
Answer: -21.92 percent

Question: What is the increase in the cash and cash equivalents from 2018 and 2019?
Facts: 2,129; 771
Derivation: 771 - (-2,129) 
Answer: 2900 thousand

Question: How many common shares were purchased in July 2017?
Facts: As part of our July 2017 private placement transaction with Mr. Schutte, we issued warrants to purchase 1,782,531 shares of our common stock.
Answer: As part of our July 2017 private placement transaction with Mr. Schutte, we issued warrants to purchase 1,782,531 shares of our common stock.

Question: What was the exercise price of that 10 million common stock for Mr. Schutte in 2019
Facts: On June 28, 2019 as part of the changes made to the loan agreements we had with Mr. Schutte, each having an original due date of January 2, 2020, we issued to him a warrant to purchase 10.0 million shares of our common stock exercisable at a price of $0.01 per share and expire five years after issuance.
Answer: On June 28, 2019 as part of the changes made to the loan agreements we had with Mr. Schutte, each having an original due date of January 2, 2020, we issued to him a warrant to purchase 10.0 million shares of our common stock exercisable at a price of $0.01 per share and expire five years after issuance.

Question: What was the expiration date of the 10 million secured promissory notes issued in December 2013? 
Facts: In connection with the issuance of the $10.0 million secured promissory notes in December 2013, we issued common stock purchase warrants (“warrants”) exercisable for 60 thousand shares of our common stock having an exercise price of $2.52 per share (after giving effect to our one-for-five reverse stock split) with an expiration date in December 2020.
Answer: In connection with the issuance of the $10.0 million secured promissory notes in December 2013, we issued common stock purchase warrants (“warrants”) exercisable for 60 thousand shares of our common stock having an exercise price of $2.52 per share (after giving effect to our one-for-five reverse stock split) with an expiration date in December 2020.

Question: What is the difference between the ending outstanding common stock purchase warrants in 2018 and 2019? 
Facts: 0.1; 0.59
Derivation: 0.59 - 0.1 
Answer: 0.49

Question: What is the percentage increase in ending outstanding common stock purchase warrants from 2018 to 2019?
Facts: 1,842; 10,000
Derivation: 10,000 / 1,842 
Answer: 542.89 percent

Question: How much was the percentage decrease in ending price of outstanding common stock purchase warrants from 2018 to 2019?
Facts: 0.10; 0.59
Derivation: (0.59 - 0.10) / 0.59 
Answer: 83.05 percent

Question: How is share-based compensation expense measured?
Facts: We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability classified instrument.
Answer: We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability classified instrument.

Question: What are the types of share-based compensation plans?
Facts: We have several share-based compensation plans covering stock options and RSUs for our employees and directors
Answer: We have several share-based compensation plans covering stock options and RSUs for our employees and directors

Question: What was the total share-based compensation in 2018?
Facts: 138
Answer: 138 thousand

Question: How much did the stock-based compensation expense in the general and administrative operations decreased from 2018 to 2019?
Facts: 117; 165
Derivation: 165 - 117 
Answer: 48 thousand

Question: How much percent did the total share-based compensation decreased from 2018 to 2019?
Facts: 138; 230
Derivation: (230 - 138) / 138 
Answer: 66.67 percent

Question: What proportion of the total stock-based compensation expense is made up from the research and development operations in 2019?
Facts: 138; 21
Derivation: 21/138 
Answer: 15.22 percent

Question: What are the two restricted stock unit award plans for employee and non-employee directors?
Facts: We have two Restricted Stock Unit Award Plans for our employees and non-employee directors, a 2017 Restricted Stock Unit Award Plan (the “2017 RSU Plan”) and a 2014 Restricted Stock Unit Award Plan (the “2014 RSU Plan”).
Answer: We have two Restricted Stock Unit Award Plans for our employees and non-employee directors, a 2017 Restricted Stock Unit Award Plan (the “2017 RSU Plan”) and a 2014 Restricted Stock Unit Award Plan (the “2014 RSU Plan”).

Question: What was the RSU liability for non-employee directors in 2019 and 2018?
Facts: The liability was $29 thousand and $11 thousand at December 31, 2019 and 2018, respectively.
Answer: The liability was $29 thousand and $11 thousand at December 31, 2019 and 2018, respectively.

Question: What is the ending outstanding number of vested RSUs in 2019?
Facts: 1,017
Answer: 1,017 thousand

Question: What is the difference between ending outstanding balance of RSUs and Vested RSUs in 2018?
Facts: 459; 951
Derivation: 951 - 459 
Answer: 492 thousand

Question: What is the difference between the number of RSUs granted in 2019 and 2018?
Facts: 333; 759
Derivation: 759 - 333 
Answer: 426 thousand

Question: What is the percentage increase in number of RSUs from 2018 to 2019?
Facts: 1,017; 951
Derivation: (1,017 - 951) / 951 
Answer: 6.94 percent

Question: What was the depreciation expense in 2018?
Facts: $73 thousand
Answer: $73 thousand

Question: What are the accounting treatments for disposed assets?
Facts: When a depreciable asset is retired from service, the cost and accumulated depreciation will be removed from the respective accounts.
Answer: When a depreciable asset is retired from service, the cost and accumulated depreciation will be removed from the respective accounts.

Question: What is the net total for property, plant and equipment in 2019?
Facts: $ 540
Answer: $ 540 thousand

Question: How much of scientific equipment is being decapitalized from 2018 to 2019? 
Facts: 597; 598
Derivation: 598 - 597 
Answer: 1 thousand

Question: How much assets were decapitalized from 2018 to 2019?
Facts: 2,509; 2,512
Derivation: 2,512 - 2,509 
Answer: 3 thousand

Question: What is the percentage decrease in Net Total Property, Plant and Equipment from 2018 to 2019?
Facts: 540; 606
Derivation: (606 - 540) / 606 
Answer: 10.89 percent

Question: What is the most significant item of the deferred tax assets?
Facts: The most significant item of our deferred tax assets is derived from our Federal NOLs.
Answer: The most significant item of our deferred tax assets is derived from our Federal NOLs.

Question: What happens to unused Federal NOL benefit according to Internal Revenue Code?
Facts: As prescribed under Internal Revenue Code, any unused Federal NOL benefit from the annual limitation can be accumulated and carried forward to the subsequent year and will expire if not used in accordance with the NOL carried forward term of 20 years or 2037, if generated before 2018 and Federal NOLs generated after 2017 can be carried forward indefinitely.
Answer: As prescribed under Internal Revenue Code, any unused Federal NOL benefit from the annual limitation can be accumulated and carried forward to the subsequent year and will expire if not used in accordance with the NOL carried forward term of 20 years or 2037, if generated before 2018 and Federal NOLs generated after 2017 can be carried forward indefinitely.

Question: Why are deferred income tax assets offset in 2018 and 2019?
Facts: At both December 31, 2019 and 2018, all our remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of NOL carryforwards.
Answer: At both December 31, 2019 and 2018, all our remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of NOL carryforwards.

Question: What is the difference between the total deferred tax in 2018 and 2019?
Facts: 4,442; 4,955
Derivation: 4,955 - 4,442 
Answer: 513 thousand

Question: How much did R&D tax credits from the Federal increased from 2018 to 2019?
Facts: 1,184; 1,207
Derivation: 1,207 - 1,184 
Answer: 23 thousand

Question: What is the increase in Net deferred tax assets from 2018 to 2019?
Facts: 0
Derivation: 0 - 0 
Answer: 0 thousand